Xenon Announces Positive Results from X-TOLE2 Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
"In the first quarter of 2026, we announced positive results from our X-TOLE2 study, which exceeded expectations and reinforced azetukalner's significant potential to provide a new therapeutic option for FOS patients with uncontrolled seizures. The strong X-TOLE2 results have paved the way for us to submit an NDA to the FDA in the third quarter of 2026 and our commercial preparedness activities are well underway, supported by our strong balance sheet with cash runway into 2029," said Ian Mortimer, President and Chief Executive Officer of Xenon. "We remain enthusiastic about broadening the opportunity for azetukalner beyond FOS and are making good progress advancing multiple additional Phase 3 studies in epilepsy and neuropsychiatry indications. Additionally, we are looking forward to completing the first-in-human studies for our novel programs targeting NaV1.7 and KV7 in pain later this year."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XENE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XENE
Wall Street analysts forecast XENE stock price to rise
14 Analyst Rating
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 53.980
Low
44.00
Averages
54.09
High
62.00
Current: 53.980
Low
44.00
Averages
54.09
High
62.00
About XENE
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Octagon Capital Acquires Stake in Xenon Pharmaceuticals
- New Investment Position: On May 15, 2026, Octagon Capital Advisors disclosed a new stake in Xenon Pharmaceuticals by acquiring 490,000 shares valued at approximately $22.58 million, indicating strong confidence in the company's growth potential.
- Value Appreciation: By the end of Q1 2026, the value of Octagon's stake in Xenon had risen to $28.49 million, reflecting significant price appreciation during the holding period and positive market sentiment towards its product pipeline.
- Strong Market Performance: As of May 14, 2026, Xenon's shares were priced at $56.00, representing an 85% increase over the past year and outperforming the S&P 500 by about 60 percentage points, showcasing its robust position in the biopharmaceutical sector.
- Promising Pipeline: Xenon's lead drug candidate, azetukalner, has shown impressive results in clinical trials for epilepsy and depression, with plans to submit a New Drug Application to the FDA in Q3 2026, further solidifying its market position.
See More
Xenon Pharmaceuticals Q1 2026 Earnings Call Highlights
- AZK Clinical Progress: Xenon highlighted in its Q1 2026 earnings call that the Phase III X-TOLE2 study results for AZK exceeded expectations, with an NDA submission to the FDA anticipated in Q3 2026, potentially leading to a market launch by late 2027 or early 2028, significantly enhancing the company's competitive edge in the epilepsy market.
- Improved Financial Position: The company ended Q1 with cash and cash equivalents of $1.3 billion, a substantial increase from $586 million at year-end, driven by a successful $747.5 million financing, which provides ample funding for operations into 2029, ensuring financial stability for upcoming projects.
- New Drug Development Plans: Management revealed ongoing Phase I trials for pain-targeting drugs XEN1701 and XEN1120, expected to complete this year, with plans to advance to Phase II proof-of-concept studies, which could open new growth avenues for the company in the pain management sector.
- Market Preparation Efforts: Xenon is actively building its commercial infrastructure and finalizing its go-to-market strategy while engaging with payers to ensure a robust competitive position for AZK upon launch, further solidifying its standing in the neuroscience field.
See More
Xenon Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Beat: Xenon Pharmaceuticals reported a Q1 GAAP EPS of -$1.17, beating expectations by $0.02, indicating a slight improvement in financial performance that may bolster investor confidence.
- Significant Cash Reserves: As of March 31, 2026, the company had $1.3396 billion in cash and cash equivalents, a substantial increase from $586 million as of December 31, 2025, reflecting a strong liquidity position that supports future operations.
- Successful Fundraising: During the quarter, Xenon raised $130 million in net proceeds through its ATM and $707.6 million through a public offering, demonstrating strong market demand for its shares and enhancing its capital base.
- Sufficient Operating Funds: Based on current operating plans, Xenon anticipates having enough cash to fund operations into 2029, indicating financial stability and sustainability for the company in the coming years.
See More
AAN Meeting: Azetukalner Significantly Reduces Seizure Frequency in Epilepsy
- Clinical Trial Results: In the X-TOLE2 study, the 25 mg group showed a 53.2% reduction in monthly seizure frequency, significantly outperforming the placebo group's 10.4%, highlighting Azetukalner's potential in treating refractory epilepsy.
- Long-term Efficacy Data: In the ongoing X-TOLE OLE study, nearly 40% of participants achieved at least 12 months of seizure freedom over 48 months, indicating the drug's effectiveness and safety in long-term use.
- Improved Patient Experience: Real-world data suggest that Azetukalner's no-titration requirement alleviates stress for both patients and physicians, simplifying epilepsy management and enhancing patients' quality of life and adherence to treatment.
- Future Development Plans: Xenon aims to submit a New Drug Application to the FDA in Q3 2026, further advancing Azetukalner's market access to meet the urgent demand for new anti-seizure medications.
See More
Xenon Pharmaceuticals Reports Significant Efficacy of Azetukalner in Epilepsy Studies
- Clinical Trial Results: The X-TOLE2 study demonstrated a 53.2% reduction in monthly seizure frequency for the 25 mg azetukalner group compared to a mere 10.4% for the placebo group, highlighting the drug's potential to transform treatment for refractory epilepsy.
- Long-term Efficacy Data: In the ongoing 48-month open-label extension study, nearly 40% of participants achieved at least 12 months of seizure freedom, with 25% achieving 24 months, indicating azetukalner's effectiveness in long-term epilepsy management.
- Improved Patient Experience: Real-world data suggest that azetukalner's no-titration feature alleviates stress for both patients and physicians, enhancing patient confidence and adherence, thereby simplifying the management of epilepsy with significant clinical implications.
- Future Development Plans: Xenon aims to submit a New Drug Application to the FDA in Q3 2026, further advancing azetukalner towards market availability, which is expected to provide a more effective treatment option for epilepsy patients.
See More
Xenon Pharmaceuticals to Present at Four Investor Conferences
- Investor Conference Schedule: Xenon Pharmaceuticals will present at four investor conferences in Q2 2026, including Bloom Burton & Co., Bank of America, RBC Capital Markets, and Jefferies, showcasing its latest advancements in neuroscience and potentially boosting investor confidence.
- Presentation Dates and Locations: The company will present on April 22, May 14, May 19, and June 4, 2026, in Toronto, Las Vegas, and New York, enhancing investor engagement and demonstrating its clinical development and commercialization strategies.
- Clinical Trial Progress: Xenon's lead molecule, azetukalner, is currently in Phase 3 trials for epilepsy, major depressive disorder, and bipolar depression, and successful advancement could significantly enhance the company's market position in the biopharmaceutical sector.
- Diverse Product Pipeline: In addition to azetukalner, Xenon is advancing multiple early-stage potassium and sodium channel modulator programs, and successful outcomes from these projects will provide more treatment options, further solidifying its leadership in the neuroscience field.
See More
Octagon Capital Acquires Stake in Xenon Pharmaceuticals
- New Investment Position: On May 15, 2026, Octagon Capital Advisors disclosed a new stake in Xenon Pharmaceuticals by acquiring 490,000 shares valued at approximately $22.58 million, indicating strong confidence in the company's growth potential.
- Value Appreciation: By the end of Q1 2026, the value of Octagon's stake in Xenon had risen to $28.49 million, reflecting significant price appreciation during the holding period and positive market sentiment towards its product pipeline.
- Strong Market Performance: As of May 14, 2026, Xenon's shares were priced at $56.00, representing an 85% increase over the past year and outperforming the S&P 500 by about 60 percentage points, showcasing its robust position in the biopharmaceutical sector.
- Promising Pipeline: Xenon's lead drug candidate, azetukalner, has shown impressive results in clinical trials for epilepsy and depression, with plans to submit a New Drug Application to the FDA in Q3 2026, further solidifying its market position.
See More
Xenon Pharmaceuticals Q1 2026 Earnings Call Highlights
- AZK Clinical Progress: Xenon highlighted in its Q1 2026 earnings call that the Phase III X-TOLE2 study results for AZK exceeded expectations, with an NDA submission to the FDA anticipated in Q3 2026, potentially leading to a market launch by late 2027 or early 2028, significantly enhancing the company's competitive edge in the epilepsy market.
- Improved Financial Position: The company ended Q1 with cash and cash equivalents of $1.3 billion, a substantial increase from $586 million at year-end, driven by a successful $747.5 million financing, which provides ample funding for operations into 2029, ensuring financial stability for upcoming projects.
- New Drug Development Plans: Management revealed ongoing Phase I trials for pain-targeting drugs XEN1701 and XEN1120, expected to complete this year, with plans to advance to Phase II proof-of-concept studies, which could open new growth avenues for the company in the pain management sector.
- Market Preparation Efforts: Xenon is actively building its commercial infrastructure and finalizing its go-to-market strategy while engaging with payers to ensure a robust competitive position for AZK upon launch, further solidifying its standing in the neuroscience field.
See More
Xenon Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Beat: Xenon Pharmaceuticals reported a Q1 GAAP EPS of -$1.17, beating expectations by $0.02, indicating a slight improvement in financial performance that may bolster investor confidence.
- Significant Cash Reserves: As of March 31, 2026, the company had $1.3396 billion in cash and cash equivalents, a substantial increase from $586 million as of December 31, 2025, reflecting a strong liquidity position that supports future operations.
- Successful Fundraising: During the quarter, Xenon raised $130 million in net proceeds through its ATM and $707.6 million through a public offering, demonstrating strong market demand for its shares and enhancing its capital base.
- Sufficient Operating Funds: Based on current operating plans, Xenon anticipates having enough cash to fund operations into 2029, indicating financial stability and sustainability for the company in the coming years.
See More
AAN Meeting: Azetukalner Significantly Reduces Seizure Frequency in Epilepsy
- Clinical Trial Results: In the X-TOLE2 study, the 25 mg group showed a 53.2% reduction in monthly seizure frequency, significantly outperforming the placebo group's 10.4%, highlighting Azetukalner's potential in treating refractory epilepsy.
- Long-term Efficacy Data: In the ongoing X-TOLE OLE study, nearly 40% of participants achieved at least 12 months of seizure freedom over 48 months, indicating the drug's effectiveness and safety in long-term use.
- Improved Patient Experience: Real-world data suggest that Azetukalner's no-titration requirement alleviates stress for both patients and physicians, simplifying epilepsy management and enhancing patients' quality of life and adherence to treatment.
- Future Development Plans: Xenon aims to submit a New Drug Application to the FDA in Q3 2026, further advancing Azetukalner's market access to meet the urgent demand for new anti-seizure medications.
See More
Xenon Pharmaceuticals Reports Significant Efficacy of Azetukalner in Epilepsy Studies
- Clinical Trial Results: The X-TOLE2 study demonstrated a 53.2% reduction in monthly seizure frequency for the 25 mg azetukalner group compared to a mere 10.4% for the placebo group, highlighting the drug's potential to transform treatment for refractory epilepsy.
- Long-term Efficacy Data: In the ongoing 48-month open-label extension study, nearly 40% of participants achieved at least 12 months of seizure freedom, with 25% achieving 24 months, indicating azetukalner's effectiveness in long-term epilepsy management.
- Improved Patient Experience: Real-world data suggest that azetukalner's no-titration feature alleviates stress for both patients and physicians, enhancing patient confidence and adherence, thereby simplifying the management of epilepsy with significant clinical implications.
- Future Development Plans: Xenon aims to submit a New Drug Application to the FDA in Q3 2026, further advancing azetukalner towards market availability, which is expected to provide a more effective treatment option for epilepsy patients.
See More
Xenon Pharmaceuticals to Present at Four Investor Conferences
- Investor Conference Schedule: Xenon Pharmaceuticals will present at four investor conferences in Q2 2026, including Bloom Burton & Co., Bank of America, RBC Capital Markets, and Jefferies, showcasing its latest advancements in neuroscience and potentially boosting investor confidence.
- Presentation Dates and Locations: The company will present on April 22, May 14, May 19, and June 4, 2026, in Toronto, Las Vegas, and New York, enhancing investor engagement and demonstrating its clinical development and commercialization strategies.
- Clinical Trial Progress: Xenon's lead molecule, azetukalner, is currently in Phase 3 trials for epilepsy, major depressive disorder, and bipolar depression, and successful advancement could significantly enhance the company's market position in the biopharmaceutical sector.
- Diverse Product Pipeline: In addition to azetukalner, Xenon is advancing multiple early-stage potassium and sodium channel modulator programs, and successful outcomes from these projects will provide more treatment options, further solidifying its leadership in the neuroscience field.
See More
